Effects of Flecainide on Cardiac Arrhythmias in ARVC Patients

Brief description of study

This study is being done to assess the safety and effects of flecainide on the cardiac arrhythmias (abnormal heart rhythms) that are experienced by persons with Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC). There is no established drug treatment for ventricular arrhythmias in ARVC patients. Flecainide is approved by the Food and Drug Administration (FDA) to treat heart arrhythmias, but has not been evaluated for use in people with ARVC. Current information on flecainide that is available to physicians and researchers shows that flecainide may reduce ventricular arrhythmias in ARVC.

Clinical Study Identifier: s18-02078
ClinicalTrials.gov Identifier: NCT03685149
Principal Investigator: Marina Cerrone.
Other Investigator: Lior Jankelson.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.